Navigation Links
So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
Date:11/15/2007

rtunity to have face-to-face dialogues with top policymakers and executives. The Summit is aimed at industry executives in all areas of responsibility who want to create successful strategies for dealing with FDA and CMS. Attendees will get practical, real-life lessons from some of the most experienced pharmaceutical and biotechnology executives on how they handle regulatory obstacles, and will also be able to benchmark their regulatory strategy against all other pharmaceutical and biotechnology companies.

Among the panels and participants scheduled for the Summit are:

- Did FDA Kill the Blockbuster? The Impact of FDA Changes on Research

and Development

-- Pfizer President, Global R&D Martin Mackay

-- Bristol-Myers Squibb SVP R&D Brian Daniels

-- Novartis SVP Global Clinical Development & Medical Affairs Glenn

Gormley

- Personalized Medicine: How Industry and Government can Make it Happen

-- Hoffmann La-Roche Inc. CEO George Abercrombie

- FDAAA and the New Active Surveillance System: What Does Data Mining

Mean for the Pharmaceutical Industry?

-- Engelberg Center for Health Care Reform Director, Former CMS

Administrator & FDA Commissioner Mark McClellan

-- FDA Assistant Commissioner for Policy Jeffrey Shuren

-- i3 Drug Safety SVP Alec Walker

- Paying for Innovation: CMS' Approach to Coverage

-- CMS Coverage & Analysis Group Director Steve Phurrough

- How the Government and Payors will Impact the Rx Market

-- CMS Center for Beneficiary Choices Chief Medical Officer Jeffrey

Kelman;

-- Former CMS Senior Advisor Larry Kocot;

-- Former Wellpoint Chief Pharmacy Officer and Founder of Doc Rock

Presents Robert Seidman

- Pharma in the Crosshairs: What are the Boundaries for Acceptable

Marketing?

-- First Assistant US Attorney, Boston Michael Loucks

-- Sidley
'/>"/>

SOURCE Windhover Information Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. Stem Cell Science Holds Opportunities as Important Tool for Diabetes Research Beyond Cell-Based Treatments
5. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
6. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
9. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Dr. Robert Hanzlik, whose ... toxicity carries implications for advancing the creation of safer ... National University , the second-largest private, nonprofit university ... Hanzlik, a professor at the University of Kansas School ... design, starts at 5 p.m. and takes place at ...
(Date:4/27/2015)...  Edico Genome today announced that collaborative data ... Stanford Universities showed the DRAGEN™ Bio-IT Processor sped ... depth of coverage by tenfold, generating results in ... standard software. "Processing large amounts of ... research and clinical labs, in terms of the ...
(Date:4/27/2015)... Deadly viruses such as Ebola are ... the University City Science Center's Port business ... With a $4.5 million Phase 2 SBIR grant from ... Therapeutics is focused on therapies for unmet medical ... is developing first-in-class protease inhibitors based on a technology ...
(Date:4/27/2015)... , 27 avril 2015 /PRNewswire/ ... médicamenteuse spécialisée dans le développement d,une ... soigner les infections bactériennes polypharmacorésistantes potentiellement ... de données prouvant les promesses de ... dans la lutte contre la résistance ...
Breaking Biology Technology:Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
... is Well-Positioned to Expand Business Development Efforts, ... Inc., a company,focused on the development of molecular ... market, announced today that Joe Ross has,joined the ... President of,Strategic Initiatives., In this new role, ...
... WARSAW, Ind., Sept. 4 Zimmer Holdings, Inc.,(NYSE: ... subsidiaries have,agreed to acquire the Abbott Spine business from ... expects to fund the purchase price,from cash on hand ... is expected to close in the fourth quarter of ...
... Ohio State University,Medical Center has invited experts from ... the laboratory to clinical health,care practice during the ... Health care leaders, government policy makers, health care ... patient,advocacy groups will be among the more than ...
Cached Biology Technology:Axial Biotech appoints new Vice President of Strategic Initiatives 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 3Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 4OSU to Host National Personalized Health Care Conference 2
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/30/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) ... Recognition Market in Automotive Sector 2014-2018" report to ... Gesture Recognition market in Automotive Sector to grow at ... Gesture recognition is the ability of a device ... individual. Gesture recognition technology can be 2D-based or 3D-based. ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... Inc. (TSX-V: IOT), a pioneer in the field of biofilm ... Ltd of Israel to market and distribute its bioFILM PA ... very excited to enter into this agreement with LevPharm, who ... on improving patient care while reducing the cost burden to ...
... blue-green algae out-compete other organisms through a form of ... in freshwater bodies -- has been described by a ... In general, the increasing occurrence of toxic cyanobacterial (blue-green ... growing international concern due to their detrimental impact on ...
... 2010 A new report, Agriculture,s Role in Greenhouse ... of Agronomy, Crop Science Society of America, and Soil ... gas (GHG) emissions and sequestration in America,s major agroecosystems. ... (CO2), nitrous oxide (N2O) and methane (CH4) emissions and ...
Cached Biology News:How algae 'enslavement' threatens freshwater bodies described by Hebrew University researcher 2US greenhouse gas emissions and capture, regionally 2
... experimental process of determining the nucleotide sequence ... Sequencing is based on Sangers enzymatic method ... cycle sequencing reactions. The resulting fluorescent products ... instrument controlled by a computer and the ...
... Anti-phospho-Lck (pTyr 192 ) The antibody is preadsorbed ... affinity isolated antibody buffered aqueous glycerol solution ... saline (without Mg 2+ and Ca 2+ ... 1.0 mg/mL BSA (IgG, protease free) and 0.05% ...
... calibration, and validation (MCV) plate ... used for hands-free startup, shutdown, ... the Bio-Plex suspension array system. ... use with Bio-Plex Manager software ...
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
Biology Products: